RGEN Stock Recent News

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Genmab A/S Sponsored ADR (GMAB) and Repligen (RGEN). But which of these two stocks is more attractive to value investors?

WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team's engagement with the investment community, reporting to the company's Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing Director, Research Analyst at Stephens Inc., where he followed the life sciences tools and pharma services sector.

Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

I reiterate a 'buy' rating for Repligen with a one-year price target of $175 per share, driven by strong bioprocessing market recovery. Repligen reported 3% organic revenue growth and 13% growth in non-COVID business, with record-high order intakes since Q2 FY22. The acquisition of 908 Devices' bioprocessing analytics portfolio enhances Repligen's process analytical technology, adding significant value to its offerings.

On Tuesday, Repligen Corporation RGEN purchased 908 Devices Inc.'s MASS desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications.

Portfolio includes PAT devices for real-time process monitoring, control and analysis Portfolio includes PAT devices for real-time process monitoring, control and analysis

WALTHAM, Mass., & BOSTON--(BUSINESS WIRE)--Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device.

RGEN reports decent fourth-quarter results and issues guidance for 2025.

Repligen Corporation (NASDAQ:RGEN ) Q4 2024 Earnings Call Transcript February 20, 2025 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Olivier Loeillot - President and Chief Executive Officer Jason Garland - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Rachel Vatnsdal - J.P. Morgan Puneet Souda - Leerink Partners Matt Larew - William Blair & Company Jacob Johnson - Stephens Inc. Conor McNamara - RBC Capital Markets Matt Hewitt - Craig Hallum Subbu Nambi - Guggenheim Securities Justin Bowers - Deutsche Bank Paul Knight - KeyBanc Capital Doug Schenkel - Wolfe Research Operator Good day, ladies and gentlemen.

Repligen Corp RGEN released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago but beating the consensus of 41 cents.